Paul-Ehrlich-Institut

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Coronavirus and COVID-19

Pagination

SARS-CoV-2 Test Systems

The Paul-Ehrlich-Institut is no longer involved in the evaluation of the SARS-CoV-2 rapid tests since 30 June 2022.

The list of CE-marked COVID-19 antigen tests (Common RAT List) was last updated on 17 May 2023. The performance of nearly 300 COVID-19 antigen tests that met stringent criteria were reviewed in additional studies and these tests were included on the list. A document with background information on the decisions of the technical working group was also made available since the last update. This document lists the tests that have been removed or were not included at all.

Common List of Coronavirus Rapid Antigen Tests (Common RAT List)

This list and the document with background information is available at the following link:

European Commisson: Public Health - Common List of Coronavirus Rapid Antigentests (Common RAT List)

The tests are listed in a table in Annex I to the document. The tests can be identified using the reference number (column: "REF number") and the commercial name of the test (column: "Commercial name of the device").

The tests on the Common List of Coronavirus Rapid Antigen Tests are also included in the Joint Research Centre (JRC) COVID-19 database for in vitro diagnostic medical devices (IVD):

European Commisson: COVID-19 In Vitro Diagnostic Medical Devices

Advanced filters can be used to display all tests included in the Common List of Coronavirus Rapid Antigen Tests [HSC common list (RAT)]. The database also enables further search function.

The European Union website also provides information on the criteria for inclusion in the Common List of Coronavirus Rapid Antigen Tests:

European Commisson: Technical working group on COVID-19 diagnostic tests

This website is available in several languages. Documents linked there are only available in English.

The market overview published by the Federal Institute for Drugs and Medical Devices (BfArM) in accordance with section 1 paragraph 1 sentence 6 of the TestV (old version) and the list containing results of the comparative evaluation of the sensitivity of SARS-CoV-2 rapid antigen tests by the Paul-Ehrlich-Institut have been discontinued.

Content

  1. Role of the Paul-Ehrlich-Institut
  2. COVID-19 Vaccines
  3. Proof of vaccination within the meaning of the Infection Protection Act (IfSG)
  4. FAQ Coronavirus
  5. Safety of COVID-19 Vaccines
  6. Research Work
  7. SARS-CoV-2 Test Systems